StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Giftify (GIFT) announced a significant increase in gift card sales following its announcement of a smart savings program for GLP-1 diabetes and ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...

Here are the most important news items that investors need to start their trading day: ...

South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over their insulin pen market practices, amid growing concerns about ...